The purpose of the Benchmark Dose Workshop was to assess the feasibility and
implications of replacing the no observed adverse effect level (NOAEL) with a benchmark …

This review deals with the current state of knowledge on the use of the benchmark dose
(BMD) concept in health risk assessment of chemicals. The BMD method is an alternative to …

The overall goal of this project is to evaluate and compare risk assessment methods
traditionally used for noncancer health risks and to compare them with new approaches …

The use of no observed adverse effect levels (NOAELs) as a way of interpreting toxicology
studies carries a number of problems, and the benchmark dose (BMD), or its lower …

Safety assessment for noncancer health effects generally has been based upon dividing a
no observed adverse effect (NOAEL) by uncertainty (safety) factors to provide an acceptable …

In this review, recent methodological developments for the benchmark dose (BMD)
methodology are summarized. Specifically, we introduce the advances for the main steps in …

Abstract The Scientific Committee (SC) reconfirms that the benchmark dose (BMD) approach
is a scientifically more advanced method compared to the NOAEL approach for deriving a …

The benchmark dose (BMD) 4 approach is emerging as replacement to determination of the
No Observed Adverse Effect Level (NOAEL) in noncancer risk assessment. This possibility …

The benchmark dose (BMD) is a dose that causes a specified low level of additional risk and
is estimated using a statistical dose-response analysis. Regulatory agencies are using a …

Traditionally, the No-Observed-Adverse-Effect-Level (NOAEL) approach has been used to
determine the point of departure (POD) from animal toxicology data for use in human health …